Hearing the words “Hodgkin lymphoma” can make the room feel as though someone quietly removed all the oxygen. The encouraging news is that Hodgkin lymphoma is one of the most treatable forms of cancer, and the goal of therapy is usually a curenot merely slowing the disease down.
Treatment commonly includes combination drug therapy, sometimes followed by radiation. Newer approaches may add immunotherapy or a targeted medicine, while stem cell transplantation is generally reserved for lymphoma that does not respond to initial treatment or returns later. The exact plan depends on the lymphoma subtype, stage, tumor size, symptoms, scan results, age, overall health, and personal priorities. In other words, Hodgkin lymphoma treatment is carefully tailored, not pulled from a one-size-fits-all medical vending machine.
What Determines a Hodgkin Lymphoma Treatment Plan?
Before treatment begins, the care team confirms the diagnosis through a lymph node biopsy. A hematopathologist examines the tissue to determine whether the disease is classical Hodgkin lymphoma or the less common nodular lymphocyte-predominant Hodgkin lymphoma, often abbreviated as NLPHL. These two forms can behave differently and may require different treatment strategies.
Doctors then stage the cancer using physical examinations, blood tests, and imagingusually a PET/CT scan. Hodgkin lymphoma is categorized as stage I, II, III, or IV, but oncologists also use practical treatment groups such as early favorable, early unfavorable, and advanced disease.
Important treatment-planning factors include:
- Whether the lymphoma is classical Hodgkin lymphoma or NLPHL
- Whether the disease is early-stage or advanced
- The presence of a bulky mass, particularly in the chest
- B symptoms, including unexplained fever, drenching night sweats, and significant unintended weight loss
- The number and location of involved lymph node regions
- Results of an interim PET/CT scan
- Heart, lung, kidney, liver, and bone marrow function
- Age, pregnancy, fertility goals, and other medical conditions
- Whether the lymphoma is newly diagnosed, refractory, or relapsed
Because Hodgkin lymphoma is uncommon and its treatments continue to evolve, consultation with a hematologist-oncologist who regularly treats lymphoma can be valuable. A second pathology review or second treatment opinion may also be reasonable before therapy starts.
The Main Treatments for Hodgkin Lymphoma
Combination Chemotherapy and Drug Therapy
Systemic drug therapy is the backbone of treatment for classical Hodgkin lymphoma. “Systemic” means the medicines circulate through the bloodstream and can reach lymphoma cells throughout the body, including those that may be too small to appear on a scan.
Drugs are usually administered in combinations because medicines that attack cancer in different ways tend to work better together. Treatment is divided into cycles, with treatment days followed by recovery time. The calendar may look suspiciously complicated at first, but the oncology team usually provides a schedule that prevents patients from having to solve it like a particularly unpleasant Sudoku puzzle.
ABVD
ABVD has been a widely used Hodgkin lymphoma chemotherapy regimen for many years. Its initials represent:
- A: Adriamycin, the brand name commonly associated with doxorubicin
- B: Bleomycin
- V: Vinblastine
- D: Dacarbazine
ABVD may be used for early-stage or advanced classical Hodgkin lymphoma. In some PET-adapted treatment plans, bleomycin is removed after the first few cycles when an interim PET scan shows a strong response. This approach may reduce the risk of lung toxicity while maintaining effective treatment.
Nivolumab Plus AVD
Nivolumab is an immune checkpoint inhibitor that helps immune cells recognize and attack cancer. When nivolumab is combined with doxorubicin, vinblastine, and dacarbazine, the regimen is commonly called N-AVD or nivolumab-AVD.
On March 20, 2026, the U.S. Food and Drug Administration approved nivolumab with AVD for adults and patients age 12 or older with previously untreated stage III or IV classical Hodgkin lymphoma. The approval followed a large randomized study in which N-AVD produced better progression-free survival than brentuximab vedotin plus AVD.
Nivolumab can cause immune-related side effects because the activated immune system may inflame healthy organs. Possible problems include thyroid disorders, skin reactions, hepatitis, colitis, pneumonitis, or changes in hormone-producing glands. These effects are often manageable when reported promptly.
Brentuximab Vedotin Plus AVD
Brentuximab vedotin is an antibody-drug conjugate. It attaches to CD30, a protein commonly found on classical Hodgkin lymphoma cells, and delivers a cancer-killing drug directly into those cells. Combined with AVD, the regimen may be called BV-AVD or A+AVD.
BV-AVD is an established option for advanced classical Hodgkin lymphoma. Potential side effects include low blood cell counts, infections, fatigue, nausea, and peripheral neuropathy. Neuropathy may feel like tingling, numbness, burning, or weakness in the hands and feet, so patients should report symptoms early rather than waiting until their toes start composing complaint letters.
Other Chemotherapy Regimens
Additional regimens, such as BrECADD and various salvage chemotherapy combinations, may be considered in selected situations. The choice depends on the patient’s risk factors, prior treatment, health, access to medications, and the experience of the treatment center.
No single regimen is automatically best for everyone. A plan that offers the strongest disease control may also carry different risks involving fertility, nerves, lungs, heart function, or infection. The oncologist’s job is to balance the likelihood of cure with both short- and long-term safety.
Radiation Therapy
Radiation therapy uses carefully directed energy to destroy lymphoma cells in a defined area. Modern Hodgkin lymphoma radiation is usually delivered as involved-site radiation therapy, or ISRT. Instead of treating large regions of the body, ISRT focuses on the areas involved when the cancer was diagnosed.
Radiation may be recommended after chemotherapy for some patients with early-stage disease, bulky tumors, or residual areas of concern. It can also be used in selected cases of relapsed lymphoma or to relieve symptoms caused by a mass.
The benefit is excellent local control. The concern is that radiation can affect nearby healthy tissue. Depending on the treated location, late effects may involve the thyroid, heart, lungs, breast tissue, or the risk of a second cancer. Modern planning, lower doses, smaller fields, breath-hold techniques, and proton therapy in selected cases can help reduce exposure.
How Treatment Changes by Stage
Early Favorable Classical Hodgkin Lymphoma
Early favorable disease generally means stage I or II lymphoma without major risk factors such as bulky tumors, B symptoms, multiple involved nodal regions, or a high erythrocyte sedimentation rate.
A common treatment approach is two to four cycles of ABVD followed by involved-site radiation. Chemotherapy alone may be appropriate for some patients, often for a longer total duration. An interim PET/CT scan helps the medical team assess the response and may influence the remaining treatment.
The decision to include radiation involves a trade-off. Adding radiation may reduce the chance of lymphoma returning in the original area, while omitting it may reduce certain long-term risks. Age, tumor location, pregnancy plans, breast and heart exposure, and the PET response all matter.
Early Unfavorable or Bulky Disease
Early-stage Hodgkin lymphoma is considered unfavorable when features suggest a higher risk of recurrence. Examples include a large chest mass, disease in several lymph node areas, B symptoms, extranodal involvement, or an elevated sedimentation rate.
Treatment is usually more intensive than it is for early favorable disease. A patient may receive four to six cycles of chemotherapy, with PET-guided adjustments and possible involved-site radiation. Radiation is considered particularly carefully when the original tumor was bulky.
Stage III or IV Classical Hodgkin Lymphoma
Advanced-stage disease is usually treated primarily with systemic therapy. Current options may include nivolumab-AVD, BV-AVD, ABVD, or another combination selected by a lymphoma specialist. Radiation is not automatically required but may be considered for a large initial mass or a residual PET-positive area.
Stage IV does not mean treatment is pointless. Hodgkin lymphoma differs from many solid tumors: even advanced disease is frequently treated with curative intent.
Why PET-Adapted Treatment Matters
A PET/CT scan performed after the first few cycles is often called an interim PET scan. It shows how metabolically active the remaining tissue is and functions as a treatment report cardalthough thankfully it does not require a parent’s signature.
A negative interim PET scan usually indicates a strong response. Depending on the original regimen and stage, doctors may reduce exposure to a drug such as bleomycin, continue the same therapy, or make decisions about radiation. A positive scan does not automatically prove that active lymphoma remains; inflammation can also absorb the radioactive tracer. Occasionally, additional imaging or a biopsy is needed before making a major treatment change.
Treatment for Relapsed or Refractory Hodgkin Lymphoma
Refractory Hodgkin lymphoma does not adequately respond to initial treatment. Relapsed lymphoma returns after a remission. Both situations are serious, but they still have potentially curative treatment options.
The next step may involve salvage therapy using a different chemotherapy combination, brentuximab vedotin, a checkpoint inhibitor such as nivolumab or pembrolizumab, or a combination of these approaches. The goal is usually to achieve a deep response before high-dose chemotherapy and an autologous stem cell transplant.
Autologous Stem Cell Transplantation
An autologous transplant uses the patient’s own blood-forming stem cells. The cells are collected and stored, after which the patient receives high-dose chemotherapy intended to destroy resistant lymphoma cells. The stored stem cells are then returned through an infusion so the bone marrow can rebuild blood production.
The procedure requires close monitoring because blood counts become extremely low for a period of time. Infection, bleeding, mouth sores, fatigue, nausea, and organ complications are possible. Despite the intimidating name, the transplanted cells are administered through an IV rather than surgically planted like tomato seedlings.
An allogeneic transplant using donor stem cells may be considered in selected patients whose lymphoma remains difficult to control after several treatments. Clinical trials may provide additional options, including new combinations of targeted agents and immunotherapies.
Treatment for Nodular Lymphocyte-Predominant Hodgkin Lymphoma
NLPHL is biologically different from classical Hodgkin lymphoma and often grows more slowly. Some people with limited disease may receive involved-site radiation. Carefully selected patients may be monitored through active surveillance after complete removal of an isolated lymph node.
Rituximab may be used because NLPHL cells commonly carry the CD20 protein. Advanced or symptomatic disease may require rituximab-based systemic therapy, chemotherapy, or a combined approach. Long-term follow-up is important because NLPHL can relapse years later and can occasionally transform into a more aggressive B-cell lymphoma.
Managing Side Effects and Protecting Long-Term Health
Supportive care is part of treatment, not an optional decorative garnish. Antinausea medications, growth factors, infection precautions, pain relief, nutrition support, counseling, and dose adjustments help patients complete therapy safely.
Common short-term concerns include:
- Fatigue that may build gradually over several cycles
- Nausea, appetite changes, or altered taste
- Hair thinning or hair loss
- Low white blood cells, anemia, or low platelets
- Infections and fever
- Mouth sores
- Constipation or diarrhea
- Peripheral neuropathy
- Skin reactions or infusion reactions
Patients should follow their cancer center’s instructions for fever. Many programs ask patients receiving chemotherapy to call immediately for a temperature of 100.4°F (38°C) or higher. There is no prize for “waiting to see whether it gets worse.”
Fertility Preservation
Fertility should be discussed before treatment begins whenever possible. Some regimens have a relatively limited effect on fertility, while high-dose chemotherapy, transplant conditioning, alkylating agents, or radiation near reproductive organs may pose greater risks.
Options may include sperm banking, egg or embryo freezing, ovarian tissue preservation, or consultation with a reproductive endocrinologist. Decisions sometimes need to be made quickly, but asking the question does not usually mean abandoning urgent cancer care.
Long-Term Follow-Up
After treatment, follow-up may include examinations, bloodwork, symptom reviews, and imaging when clinically appropriate. Survivorship care also considers the therapies a patient received. Monitoring may be needed for thyroid dysfunction, heart disease, lung problems, infertility, bone health, emotional health, and second cancers.
Patients should keep a treatment summary listing chemotherapy medicines, cumulative doses when available, radiation fields and doses, transplant details, and major complications. Twenty years later, “I had the red medicine and something beginning with B” is understandable but not especially helpful to a new physician.
What Hodgkin Lymphoma Treatment Often Feels Like: Practical Experiences
No two patients experience Hodgkin lymphoma treatment in exactly the same way. One person may continue working part-time, while another needs extended leave. Some feel reasonably well for several days after an infusion and then experience delayed fatigue. Others feel tired almost immediately but improve before the next appointment. The variability can be frustrating because cancer apparently declined to read the scheduling handbook.
The first treatment day is often the longest emotionally. Patients may have laboratory tests, a medical examination, medication teaching, an IV or port accessed, preventive medicines, and several infusions. The unfamiliar equipment and terminology can make the process feel overwhelming. After a few visits, many patients develop a routine: comfortable clothes, a phone charger, headphones, snacks approved by the care team, and a designated person who knows when not to send twelve cheerful messages before breakfast.
Fatigue is among the most common experiences. It is not always the pleasant kind of tiredness solved by a good nap. Cancer-related fatigue may feel like the body has switched to low-power mode. Patients often learn to divide chores into smaller tasks, accept help, schedule demanding activities during higher-energy periods, and take short walks when medically appropriate. Gentle activity can help some people maintain strength, but exercise goals should be adjusted to blood counts, infection risk, neuropathy, dizziness, and medical advice.
Food can become unexpectedly complicated. Familiar meals may taste metallic, bland, excessively sweet, or simply wrong. Smaller meals, cold foods, tart flavors, plastic utensils, protein-rich snacks, and regular hydration may help, depending on the person’s symptoms. A registered oncology dietitian can offer individualized guidance. This is usually more useful than an online stranger insisting that one heroic smoothie can outsmart lymphoma.
Hair loss or thinning can carry more emotional weight than outsiders realize. It makes an invisible diagnosis visible. Some patients cut their hair short before it begins shedding, while others wait. Wigs, hats, scarves, or a bare head are all valid choices. The correct look is the one that helps the patient feel most like themselves.
Interim scan day can bring “scanxiety”a mixture of hope, dread, and an impressive ability to interpret every delayed phone call as a catastrophe. It helps to ask in advance when results will be available, who will explain them, and whether the scan could show inflammation rather than active cancer. Patients should avoid attempting to diagnose themselves from a single sentence in a radiology portal before their oncologist has reviewed the full clinical picture.
Emotions may also change throughout treatment. At diagnosis, people are often focused on making decisions. During therapy, they may move into survival mode. Anxiety, sadness, anger, irritability, guilt, and fear of recurrence may emerge later, even after a complete response. Counseling, peer support, social workers, support groups, and psychiatric care can be as legitimate as medications for nausea or pain.
Caregivers have their own treatment experience. They may organize transportation, track medicines, prepare meals, attend appointments, manage insurance calls, and quietly worry at 2 a.m. Clear division of tasks helps. A shared calendar or group message can prevent one caregiver from becoming the unpaid chief operating officer of the entire family.
Returning to ordinary life after treatment may be surprisingly difficult. Friends may celebrate the final infusion as the finish line, while the patient still faces fatigue, follow-up visits, financial stress, body changes, and fear before scans. Recovery is usually gradual. A survivorship plan, realistic expectations, and permission to rebuild routines slowly can make the transition easier.
Perhaps the most useful practical lesson is to report symptoms early. Nausea, constipation, numb fingers, shortness of breath, fever, mood changes, or sleep problems may be treatable. Oncology teams cannot fix problems they do not know exist, and patients do not receive bonus points for suffering silently.
Questions to Ask the Oncology Team
- What subtype and stage of Hodgkin lymphoma do I have?
- Is my disease considered favorable, unfavorable, bulky, or advanced?
- Which regimen do you recommend, and why?
- Will an interim PET/CT scan change the treatment plan?
- Might I need radiation therapy?
- How could treatment affect my heart, lungs, nerves, thyroid, or fertility?
- Which symptoms require an immediate call?
- Should I receive growth-factor support or preventive medicines?
- Would a clinical trial be appropriate?
- What long-term survivorship screening will I need?
Conclusion
Hodgkin lymphoma is usually treated with combination drug therapy, sometimes followed by involved-site radiation. Early disease may require a shorter course, while stage III or IV classical Hodgkin lymphoma may be treated with regimens such as nivolumab-AVD, BV-AVD, or ABVD. PET/CT results help doctors adapt treatment and avoid unnecessary exposure when possible.
If lymphoma returns or fails to respond, checkpoint inhibitors, brentuximab vedotin, salvage chemotherapy, radiation, and autologous stem cell transplantation may still provide a path toward long-term remission or cure. NLPHL follows a different playbook and may be managed with radiation, rituximab-based therapy, systemic treatment, or active surveillance.
The best treatment plan is not merely the strongest collection of medicines available. It is the strategy most likely to eliminate the lymphoma while protecting the patient’s health, fertility, function, and future. That requires expert pathology, thoughtful staging, PET-guided decisions, supportive care, and honest conversations between the patient and an experienced lymphoma team.
Medical note: This article provides general educational information based on current U.S. government, cancer-organization, and major cancer-center resources available through August 2026. It does not replace diagnosis or individualized treatment recommendations from a qualified oncology team.
